Table 5.
Sensitivity analysis of the seven high dose trials from the primary analysis and the seven eligible high dose trials that did not meet the criteria for the primary analysis
| Study (daily dose of vitamin D) | Number of participants | Number of fallers/total treated | Number of fallers/total control | Effect relative risk | Lower 95% CI | Upper 95% CI | Q test P value | I2 | Fall reduction |
|---|---|---|---|---|---|---|---|---|---|
| Pooled primary analysis of the seven high dose trials (w1(800),w2,w3,w4,w5,w6,w7) | 1921 | 435/959 | 528/962 | 0.81 | 0.71 | 0.92 | 0.12 | 41% | -19% |
| Sensitivity analysis including the seven high dose trials that did not meet criteria for primary analysis | |||||||||
| Grant et al, 2005w9 (800 IU D3) | 5292 | 380/2649 | 381/2643 | 1.00 | 0.87 | 1.14 | — | — | — |
| Trivedi et al, 2003w10 (800 IU D3) | 2038 | 254/1027 | 261/1011 | 0.96 | 0.83 | 1.11 | — | — | — |
| Chapuy et al, 2002w11 (800 D3) | 583 | 251/393 | 118/190 | 1.03 | 0.90 | 1.17 | — | — | — |
| Kärkkäinen et al, 2007w12 (800 IU D3) | 3432 | 180/1718 | 209/1714 | 0.86 | 0.71 | 1.04 | — | — | — |
| Law et al, 2006 w13 (1100 IU D2) | 3717 | 770/1762 | 833/1955 | 1.03 | 0.95 | 1.10 | — | — | — |
| Harwood et al, 2004w14 (800 IU D3) | 76 | 7/39 | 13/37 | 0.51 | 0.23 | 1.11 | — | — | — |
| Latham et al, 2003w15 (1600 IU D2) | 222 | 64/108 | 60/114 | 1.13 | 0.89 | 1.42 | — | — | — |
| Pooled sensitivity analysis (w1(800),w2,w3,w4,w5,w6,w7,w9,w10,w11,w12,w13,w14,w16) | 17 281 | 2341/8655 | 2403/8626 | 0.92 | 0.85 | 0.99 | 0.006 | 56% | -8% |
Q test: P<0.100 indicates heterogeneity.
I2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.